ziopharm.comZiopharm Oncology LinkedIn

Skip to content Toggle navigation Investors Investors Home Press Releases Stock Performance SEC Filings Events & Presentation Corporate Governance Shareholder Services Email Alerts Contact Careers T-Cell Therapy Overview TCRs for Solid Tumors CAR-T Therapies Controlled IL-12 Pipeline Patients & Caregivers Overview Resources for cancer patients and caregivers Expanded Access About Overview Management Team Board of Directors Partnerships News & Publications Press Releases Scientific and Medical Publications Videos T-Cell Therapy Overview TCRs for Solid Tumors CAR-T Therapies Controlled IL-12 Pipeline Patients & Caregivers Overview Resources for cancer patients and caregivers Expanded Access About Overview Management Team Board of Directors Partnerships News & Publications Press Releases Scientific and Medical Publications Videos Careers Contact Investors Press Releases Stock Performance SEC Filings Events & Presentation Corporate Governance Shareholder Services Email Alerts Privacy Policy Terms and Conditions T-Cell Therapy Overview TCRs for Solid Tumors CAR-T Therapies Controlled IL-12 Pipeline Patients & Caregivers Overview Resources for cancer patients and caregivers Expanded Access About Overview Management Team Board of Directors Partnerships News & Publications Press Releases Scientific and Medical Publications Videos Multi-Platform Approach Addressing Solid Tumors with Non-Viral T-Cell Therapies and Cytokine-Driven Technology Sleeping Beauty Rapid Non-Viral Genetic Modification of TCR-T and CAR-T Cells Controlled IL-12 Turning Cold Tumors Hot by Activating an Immune Response Developing non-viral and cytokine-driven cell and gene therapies to effectively access and treat the millions of people diagnosed globally each year with solid tumors by weaponizing the body’s immune system. Leveraging its multi-platform approach, Ziopharm is at the forefront of immuno-oncology. Aug 6, 2020 Ziopharm Oncology Reports Second Quarter 2020 Financial Results and Provides Corporate Update Jul 28, 2020 Ziopharm Oncology to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020 Jul 22, 2020 Ziopharm Oncology Names James Huang to Board of Directors Our focus at Ziopharm is to reestablish the immune system and allow the body’s own defenses to destroy tumors. Sleeping Beauty T-Cell Therapy Sleeping Beauty is one of the most clinically advanced non-viral cell therapy platforms that genetically modifies T cells to express tumor-targeting receptors, TCR or CAR. This technology enables a new, scalable approach to manufacturing cell therapy products called Rapid Personalized Manufacturing or RPM. It has the potential to produce these therapies in a fraction of the time and cost compared to what’s currently available. Controlled IL-12 Interleukin 12, or IL-12, is a master regulator of the immune system. Ziopharm uses it to weaponize the immune system and call T cells deep into tumors. With its gene therapy technology, Ziopharm precisely controls expression of IL-12 to ensure the best possible response to treatment. Controlled IL-12 is currently being studied in recurrent glioblastoma and pediatric brain tumors. Helping patients leverage the power of the immune system in the fight against cancer. © 2020 Ziopharm Oncology, Inc. Privacy Policy Terms and Conditions Contact Twitter LinkedIn...